Skip to main content
Fig. 7 | BMC Immunology

Fig. 7

From: Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants

Fig. 7

Percentages of patients with different VEGF-specific IgG subclasses in the weeks 5–16, 20–36 and 46–56. In each of these stages, and for the available patients, the study was made in the sample with the highest specific IgG antibody titer. “n” represents the number of evaluated patients. Terms “non-detectable”, “detectable” and “predominant” are detailed in Methods

Back to article page